Application of flutamide in treatment of head and neck squamous cell carcinoma and attenuated synergistic composition of flutamide

Through the combined use of flutamide and platinum chemotherapy drugs, the problem of poor response and major adverse reactions in the treatment of head and neck squamous cell carcinoma has been solved, and better anti-cancer effects and lower adverse reactions have been achieved. The scope of application of flutamide has been expanded and new strategies for the treatment of head and neck squamous cell carcinoma.

CN119074708APending Publication Date: 2024-12-06ZHEJIANG PROVINCIAL PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411166773.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Platinum chemotherapy drugs have poor response and large adverse reactions in the treatment of head and neck squamous cell carcinoma, which limits their clinical application.

Method used

Flutamide is used in combination with platinum chemotherapy drugs (such as cisplatin, carboplatin, oxaliplatin), and flutamide is used: the mass ratio of platinum chemotherapy drugs is 75:2, flutamide 25mg/kg once a day , platinum chemotherapy drugs 2mg/kg once every 3 days, significantly reducing the adverse reactions of platinum chemotherapy drugs.

Benefits of technology

The anti-cancer effect was achieved by reducing the dosage of platinum chemotherapy drugs by half, significantly reducing the adverse reactions related to platinum chemotherapy drugs, expanding the scope of application of flutamide, and providing a new strategy for the treatment of head and neck squamous cell carcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074708A_ABST
    Figure CN119074708A_ABST
Patent Text Reader

Abstract

The invention discloses application of flutamide in treatment of head and neck squamous cell carcinoma and an attenuated synergistic composition of flutamide, and application of flutamide in preparation of anti-cancer drugs for treatment of head and neck squamous cell carcinoma. The application range of flutamide is expanded, and a new strategy is provided for treatment of head and neck squamous cell carcinoma; the flutamide and the platinum chemotherapeutic drugs are combined for use, and the dosage of the platinum chemotherapeutic drugs is only half of the conventional dosage, so that the adverse reactions related to the platinum chemotherapeutic drugs can be effectively reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of anticancer treatment, and in particular to an application of flutamide in treating head and neck squamous cell carcinoma and a toxicity-reducing and synergistic composition thereof. Background Art

[0002] Flutamide is a non-steroidal anti-androgen drug. Its main function is to bind to androgen receptors in target tissues, block the binding of dihydrotestosterone (the active form of androgen) to androgen receptors, inhibit the uptake of testosterone by target tissues, and play an anti-androgen role. Its indications mainly include the treatment of prostate cancer or benign prostatic hypertrophy. It prevents the growth and spread of cancer cells by interfering with the effects of androgens in the body.

[0003] Platinum chemotherapy drugs are widely used chemotherapy drugs, the most common of which are cisplatin, carboplatin, oxaliplatin, etc. They are mainly used to treat various types of cancer, including ovarian cancer, lung cancer, head and neck squamous cell carcinoma, and bladder cancer. Its mechanism of action is mainly through forming cross-links with urea bases on DNA to form DNA adducts, which prevent DNA repair, cause DNA damage, and ultimately induce apoptosis of cancer cells. Common adverse reactions include hepatotoxicity, nephrotoxicity, nausea and vomiting, etc. Close observation is required during use, and appropriate treatment and adjustment of medication regimen should be carried out when necessary.

[0004] Head and neck tumors are one of the most deadly malignant tumors in humans. In recent years, there have been 130,000 new cases in my country each year, and the number is increasing year by year. Head and neck squamous cell carcinoma is the main pathological type of head and neck tumors, accounting for about 90% of all cases, and is prone to occur in anatomical parts with important physiological functions such as the lips, mouth, and throat. Due to the special affected parts, the lesions and treatments will have a serious impact on the patient's appearance and important physiological functions such as breathing, swallowing, and language. Platinum drugs are common chemotherapy drugs in the chemotherapy regimen for head and neck squamous cell carcinoma, but they have disadvantages such as poor response and large adverse reactions, which greatly limit their clinical application. Summary of the invention

[0005] The purpose of the present invention is to provide an application of flutamide in treating head and neck squamous cell carcinoma and a toxicity-reducing and synergistic composition thereof, which expands the application scope of flutamide and provides a new strategy for the treatment of head and neck squamous cell carcinoma; flutamide is used in combination with platinum chemotherapy drugs, and the dosage of the platinum chemotherapy drugs is only half of the conventional dosage, which can effectively reduce the adverse reactions associated with platinum chemotherapy drugs.

[0006] The technical solution adopted by the present invention to solve its technical problem is: Application of flutamide in the preparation of anticancer drugs for treating head and neck squamous cell carcinoma.

[0007] The inventor accidentally discovered a new action pathway of flutamide during the research, thereby discovering a new indication for flutamide - head and neck squamous cell carcinoma.

[0008] The toxicity-reducing and synergistic composition for treating head and neck squamous cell carcinoma is composed of flutamide and platinum chemotherapy drugs. The present invention uses flutamide in combination with platinum chemotherapy drugs, and unexpectedly finds that flutamide and platinum chemotherapy drugs have significant synergistic effects. Based on this, the dosage of platinum chemotherapy drugs is only half of the conventional dosage to achieve a better anti-cancer effect, which can effectively reduce the adverse reactions related to platinum chemotherapy drugs and achieve significant toxicity-reducing and synergistic effects.

[0009] The platinum chemotherapy drug is selected from one of cisplatin, carboplatin and oxaliplatin.

[0010] The mass ratio of flutamide: platinum chemotherapy drugs = 75:2.

[0011] The dosage of flutamide is 25 mg / kg, once a day; the dosage of platinum chemotherapy drugs is 2 mg / kg, once every 3 days.

[0012] The use of the toxicity-reducing and synergistic-enhancing composition in the preparation of anticancer drugs for treating head and neck squamous cell carcinoma.

[0013] The beneficial effects of the present invention are: expanding the application scope of flutamide and providing a new strategy for the treatment of head and neck squamous cell carcinoma; flutamide is used in combination with platinum chemotherapy drugs, and the dosage of the platinum chemotherapy drugs is only half of the conventional dosage, which can effectively reduce the adverse reactions associated with platinum chemotherapy drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 This is a figure that explores the effect of flutamide combined with low-dose cisplatin on the treatment of HNSCC in the present invention. Figure (A) is a diagram showing the changes in tumor volume after different treatments in a tumor-bearing mouse model (n=6); Figure (B) is a diagram showing the changes in weight of mice after different treatments in a tumor-bearing mouse model (n=6); Figure (C) detects the mean fluorescence intensity (MFI) of MHC II in different groups by flow cytometry (n=6); Figure (D) detects the mean fluorescence intensity (MFI) of CD86 in different groups by flow cytometry (n=6); Figure (E) detects the mean fluorescence intensity (MFI) of CD80 in different groups by flow cytometry (n=6); Figure (F) detects the mean fluorescence intensity (MFI) of CD40 in different groups by flow cytometry (n=6); Figure (G) detects CD107A by flow cytometry respectively. + Granzyme B + , TNF-α + IFN-γ + In different groups, CD8 +The proportion of T cells (n = 6). ns, no significant difference; *p, p < 0.05; **p, p < 0.01; ***p, p < 0.01. In the figure, PBS represents phosphate buffered saline as the negative control group, Flutamide represents the flutamide group, N-PT represents the normal dose cisplatin group, L-PT represents the low dose cisplatin group, and L-PT+Flutamide low dose cisplatin and flutamide combined group.

[0015] Figure 2 This is a diagram of the present invention exploring the therapeutic effect of cisplatin combined with flutamide on HNSCC tumors through a primary HNSCC tumor model. Figure 2 (A) Schematic diagram of the construction of the chemically induced primary mouse model of HNSCC; Figure 2 (B) is a statistical diagram of pathological tissue grading of the tongue of mice after drug treatment (n=6). The pathological grading is divided into atypical hyperplasia (dysplasia), carcinoma in situ (carcinoma insitu) and invasive carcinoma (invasive carcinoma); Figure 2 (C) Immunofluorescence analysis of tongue tissues of mice after drug treatment. CK5 is a keratin 5 marker for squamous cells, Ki-67 is a proliferation index, and the proportion of CK5 and Ki-67 double-positive cells in CK6 squamous cells was counted (n=6); Figure 2 (DG) are blood routine and blood biochemical indexes in mice, Figure D is white blood cell count, Figure E is red blood cell count, Figure F is aspartate aminotransferase AST. Figure G is alanine aminotransferase ALT (n=3). ns, no significant difference; *p, p<0.05; **p, p<0.01; ***p, p<0.01. In the figure, PBS represents phosphate buffered saline as the negative control group, Flutamide represents flutamide group, N-PT represents normal dose cisplatin group, L-PT represents low dose cisplatin group, L-PT+Flutamide low dose cisplatin and flutamide combined group.

[0016] Figure 3 The present invention explores the effect of flutamide on CD8 + Diagram showing investigation of T cell activation. Figure 3 (A) Isolation and culture of human peripheral blood mononuclear cells (PBMCs) CD8 + Schematic diagram and sorting diagram of T cells. Figure 3 (B) Sorting and cultivation CD8 + T cells were stimulated with anti-CD3, anti-CD28 and IL-15 for 8 days, and then treated with flutamide or dihydrotestosterone (DHT) in the model control group. Flow cytometry was used to analyze the effector CD8+ T cells (Teff, CD8 + CD45RO - CCR7 - CD62L - CD95 + ) of total CD8 + The proportion of T cells (n = 6) in the flutamide group was significantly higher than that in the model control group. + The proportion of T cells increased by 12%. ns, no significant difference; *p, p<0.05; **p, p<0.01; ***p, p<0.01. DETAILED DESCRIPTION

[0017] The technical solution of the present invention is further described in detail below through specific embodiments.

[0018] In the present invention, unless otherwise specified, the raw materials and equipment used can be purchased from the market or are commonly used in the art. The methods in the following embodiments, unless otherwise specified, are all conventional methods in the art.

[0019] Embodiment 1: 1. Materials and Methods 1.1 The chemotherapy drug is cisplatin (Shanghai Slake Company). The head and neck squamous cell carcinoma (HNSCC) mouse cell line used in the present invention is SCC-7 cells, which were donated by Shanghai Jiaotong University. The cell species was determined to be mouse by STR identification, and 1×10 5 The cells were inoculated into the tongue of mice. One week after the tumor was formed, the tissue was subjected to histopathological examination. Two senior pathologists determined that the tissue was head and neck squamous cell carcinoma.

[0020] 1.2 The cells used in the animal experiments of the present invention were cultured in RPMI 1640 complete medium (containing 10% serum and 1% double antibody, commercially available) in a 37°C constant temperature incubator containing 5% carbon dioxide, and the cells were passaged every other day. The mice used in the present invention were C3H 4-week-old male mice (Southern Model Organisms Co., Ltd.), and 5 mice per cage were placed in a constant temperature and humidity animal room. All operations were in accordance with the regulations of the Animal Ethics Committee of Zhejiang Provincial People's Hospital. 2×10 5The cells were inoculated on the back of mice, and tumor measurements and drug treatment were performed one week later. According to previous literature, the normal dose of cisplatin in mouse experiments is 4 mg / kg, which is injected intraperitoneally once every 3 days. The concentration of low-dose cisplatin is half of the normal dose, that is, 2 mg / kg, which is injected intraperitoneally once every 3 days. The human dose of flutamide is 250 mg three times a day. Based on previous literature and human-mouse drug dose conversion, the drug dose for mice in the present invention is set to 25 mg / kg, which is injected subcutaneously into mice once a day. During the animal experiment, the tumor and mouse weight were measured every 3 days. When the mouse tumor grew to 2000mm 3 Or when the body weight decreased by 20%, the mice were killed by cervical dislocation and registered.

[0021] 1.3 Chemically induced primary HNSCC tumor model mice in the present invention were 4-week-old C57BL / 6 mice, which were randomly divided into groups according to body weight, with 8 mice in each group. The mice were modeled with 4-NQO chemical drugs (50 μg / mL). 4-NQO was dissolved in the sterile drinking water of the mice and replaced twice a week. The changes in the tongue of the mice were observed, and the weight was weighed and recorded. After 16 weeks, PBS, flutamide (25 mg / kg / d), normal dose cisplatin (4 mg / kg / q3d) and low dose cisplatin (2 mg / kg / q3d) and flutamide (25 mg / kg / d) + low dose cisplatin (2 mg / kg / q3d) were used in combination groups, and q3d means once every three days.

[0022] 1.4 The analysis of tumor immune infiltrating cells in the present invention was performed after the mice were killed by cervical dislocation. The tumor tissue was removed (including the tumor capsule), 1 / 3 of the tumor tissue was fixed in paraformaldehyde for subsequent tissue section immunofluorescence analysis, 1 / 3 of the tissue was frozen in liquid nitrogen and stored in a -80°C refrigerator for subsequent protein detection, and the remaining 1 / 3 of the tissue was cut into pieces for tumor immune infiltrating cell analysis. The tissue digestion solution contained collagenase I at a concentration of 1 mg / mL and DNase I at a concentration of 200ug / mL in 37°C RPMI1640 complete culture medium. The tissues were immersed in the tissue digestion solution and then shaken at 150rpm in a 37°C constant temperature water bath shaker for 1h, and then the cell suspension was filtered with a 70μm filter, and the cells were counted after lysing at room temperature for 3min using red blood cell lysis solution. The single cell suspension was centrifuged (1200rpm, 5min), and the cells were resuspended with 40% Percoll. Add 4 mL of 80% Percoll to a new 15 mL centrifuge tube in advance, and then use a pipette to carefully add 4 ml of 40% Percoll containing tumor cells along the wall slowly and gently on top of the 80% Percoll. Centrifuge at 350g for 30 minutes (ascending speed is 1, descending speed is 1), and the junction of 40% Percoll and 80% Percoll is the immune cells. The separated immune cells were analyzed by flow cytometry, and the flow cytometry antibody (Biolegend) used information is as follows (Anti-mouse-CD86-Brilliant Violet 650 TM , Anti-mouse-CD11c-APC, Anti-mouse-CD80-Brilliant Violet 605 TM , Anti-mouse-CD40-PerCP / Cyanine5.5, Anti-mouse-IFN-γ-APC, Anti-mouse-TNF-α-PE, Anti-human / mouse-Granzyme B-Brilliant Violet 421 TM , Anti-mouse-CD107A(LAMP-1)-PE, Anti-mouse-CD8a-Brilliant Violet 510 TM , Anti-mouse-TIGIT(Vstm3)-PE / Cyanine 7, Anti-mouse-CD279(PD-1)-PerCP / Cyanine5.5, Anti-mouse-CD45-PE / Cyanine7).

[0023] (1) Analysis of cell surface antigen expression: Take the cells to be tested in good condition, discard the supernatant and collect the cell precipitate. Dilute the flow cytometry antibody in complete culture medium (containing RPMI-1640 and 10% serum) at 1:100 and mix well. Add 50μL / tube system to a 1.5mL centrifuge tube containing cell precipitate, blow and mix thoroughly with a pipette tip, and incubate at 4℃ for 15min in a dark environment. Then add 500μL of complete culture medium solution to terminate the staining, and after slight shaking, transfer to the flow tube for detection; Intracellular factor detection: Take the cells to be detected in good condition, discard the supernatant and collect the cell precipitate. Dilute the flow cytometry antibody at 1:100 in complete culture medium (containing RPMI-1640 and 10% serum) and blow it evenly. Add 50μL / tube system to a 1.5mL centrifuge tube containing cell precipitate, blow it with a gun tip to mix it thoroughly, and incubate it at 4℃ in a dark environment for 15min. Then add 500μL RPMI-1640 solution to terminate the staining, centrifuge it at 1000rpm for 5min, discard the supernatant, and then add Fix&Perm solution according to the reagent manufacturer's instructions to break the cell membrane / nuclear membrane. After using 500μL Wash Buffer to terminate the cell membrane / nuclear membrane, centrifuge it at 1000rpm for 5min, discard the supernatant, mix the flow cytometry antibody at 1:100 Wash Buffer, and incubate it at 4℃ in a dark environment for 30min for staining. Add 500μWash Buffer to terminate the staining, and transfer it to the flow tube for detection after slight shaking.

[0024] 1.5 The tissue immunofluorescence technique used in this study is as follows: After the paraffin sections were soaked in xylene solution for 5 minutes, they were soaked in seven alcohol solutions with decreasing concentrations of 100%-50% in turn for 2 minutes each, and then soaked in distilled water for 5 minutes twice, and PBS for 5 minutes twice. Then, the slides were placed in antigen repair solution, boiled for 20 minutes, cooled to room temperature, washed with PBS 3 times, blocked with 5% BSA in PBS solution, at room temperature for 1 hour, and then washed with PBS once. Cytokeratin 5 (CK-5) was selected as a marker for squamous epithelial cells, and Ki-67 was selected as a proliferation marker. The primary antibody prepared with 5% BSA-PBS was added dropwise and incubated overnight at 4°C. PBS was washed at room temperature for 5 minutes, 3 times, and then the secondary antibody prepared with 5% BSA-PBS was added dropwise for 1 hour at room temperature, and then washed with PBS at room temperature for 5 minutes, 3 times. The slides were sealed with a mounting medium with DAPI and then stained and scanned.

[0025] The statistical method adopted by the present invention is as follows: Figure 1 The changes of tumor volume and body weight were analyzed by rank sum test, and the proportion of tumor immune infiltrating cells was analyzed by Student's T test. Figure 2The chi-square test was used for the analysis of pathological grading, and the Student's T test was used for the other analyses.

[0026] 2. Results Analysis like Figure 1 As shown, when a normal dose of cisplatin was given, the tumor growth of mice was significantly inhibited, but the weight of mice also showed a significant downward trend. When a low dose of cisplatin was used in combination with flutamide, it could significantly enhance the inhibitory effect on HNSCC tumors while having no significant effect on the weight of mice. Further analysis of tumor immune infiltrating cells revealed that the proportion of dendritic cells increased significantly after the combination of drugs, and that the killing function of CD8+T cells was significantly enhanced, suggesting that a low dose of cisplatin can activate antigen presenting cells and enhance the function of CD8+T cells. The details are as follows: Figure 1 (A) When low-dose cisplatin was used in combination with flutamide, the tumor volume was reduced by 74.87% and the tumor weight was reduced by 76.96% compared with the control group, indicating that the combination of low-dose cisplatin and flutamide has a good anti-tumor effect. Figure 1 (B) When low-dose cisplatin was used in combination with flutamide, the body weight of mice increased by 8.69% compared with the initial body weight, while the body weight of mice in the normal cisplatin group decreased by 8.61%, indicating that the combination of low-dose cisplatin and flutamide can alleviate the side effects of cisplatin treatment to a certain extent. Figure 1 (CF) shows the changes in mean fluorescence intensity (MFI) of antigen presenting cells in flow cytometry analysis after low-dose cisplatin combined with flutamide. The results show that compared with the control group, the MFI of MHCII increased by 53.84% (C), the MFI of CD86 increased by 34.26% (D), the MFI of CD80 increased by 105.75% (E), and the MFI of CD40 increased by 48.63% (F). This suggests that low-dose cisplatin combined with flutamide has an activating effect on antigen presenting cells.

[0027] like Figure 2 As shown in the results, the tumor infiltration degree was significantly reduced after the combination of low-dose cisplatin and flutamide. At the same time, after monitoring the blood routine and liver function of mice, it was found that normal doses of cisplatin had obvious bone marrow suppression and liver function damage, but when low-dose cisplatin was combined with flutamide, no obvious bone marrow transplantation and liver function damage were found, indicating that the combination of low-dose cisplatin and flutamide has good biosafety. The details are as follows: Figure 2 (C) When low-dose cisplatin was used in combination with flutamide, the proportion of CK5 and Ki-67 double-positive cell subpopulations in CD5-positive cells decreased by 45.71% compared with the control group, indicating that the combination of low-dose cisplatin and flutamide has a good anti-tumor effect. Figure 2(D) shows the white blood cells (WBC) of mice after low-dose cisplatin combined with flutamide. The results show that compared with the control group, the WBC decreased by 16.78% after low-dose chemotherapy combined with flutamide, while the WBC of mice in the normal cisplatin dose treatment group decreased by 66.90%, indicating that the combination of low-dose cisplatin and flutamide can alleviate the side effects of bone marrow suppression caused by cisplatin. Figure 2 (E) shows the changes in red blood cells (RBC) of mice after low-dose cisplatin combined with flutamide. The results showed that compared with the control group, the RBC decreased by 6.33% after low-dose chemotherapy combined with flutamide, while the WBC of mice in the normal cisplatin dose treatment group decreased by 17.16%. Figure 2 (FG) shows the changes in liver function of mice after low-dose cisplatin combined with flutamide. The results showed that compared with the control group, alanine aminotransferase (ALT) increased by 50.18% and aspartate aminotransferase (AST) increased by 135.03% after low-dose chemotherapy combined with flutamide, while ALT of mice in the normal cisplatin dose treatment group increased by 179.69% and AST increased by 331.98%, indicating that the combination of low-dose cisplatin and flutamide can reduce the side effects of liver damage caused by cisplatin.

[0028] Table 1 Tumor inhibition rate and synergistic index of flutamide and low-dose cisplatin in the treatment of HNSCC tumors The present invention uses the literature method (Wu Yongzhong, Ren Qinglan, Li Shaolin. The therapeutic effect of C-erbB-2 and c-raf-1 gene antisense oligonucleotides on subcutaneous transplanted tumors of human ovarian cancer in nude mice. Cancer, 200322 (8): 836-839) to calculate whether the drug combination has a synergistic therapeutic effect according to the formula EAB / (EA+EB-EA*EB), where EAB is the tumor inhibition rate when the two drugs are used in combination, and EA and EB are the tumor inhibition rates (CI) when the two drugs are used alone. Result = 1 means the effects of the two drugs are added, result < 1 means drug antagonism, and result > 1 means the drugs act synergistically. According to the calculation, it was found that the synergistic index reached 3.41, which is significantly greater than 1, indicating that low-dose cisplatin and flutamide have a significant synergistic effect.

[0029] Flutamide pathway research methods: human Analysis of CD8+T cells: 5 ml of blood was collected from the patient's cubital venous blood each time and injected into an anticoagulant tube (gently shake the anticoagulant tube to allow the blood to fully contact the anticoagulant to prevent blood coagulation). According to the instructions of the OptiPrepTM (Serumwerk Bernburg) reagent, B solution (0.85% NaCl, 30 mM Tricine-NaOH, pH 7.4), C solution (0.85% NaCl, 10 mM Tricine-NaOH, pH 7.4), Working Solution (4 ml OptiPrepTM and 2 ml B solution) and Density Barrier Solution (5 ml Working Solution and 9.6 ml C solution) were prepared respectively. 5 ml of whole blood, 5 ml of Density Barrier Solution and 0.5 ml of C solution were added to a 15 ml five-bacteria centrifuge tube in sequence. Centrifuge at 700g for 20 minutes at room temperature. Note that the centrifugal speed is adjusted to 1 for the ascending speed and 1 for the descending speed. After centrifugation, you can see the solution is layered. The peripheral blood mononuclear cells are located on the red blood cell layer. Use a pipette to carefully suck out the peripheral blood mononuclear cells into a clean 15ml centrifuge tube. Add 1xPBS 5mL to wash and centrifuge at 1000rpm for 5 minutes at room temperature to obtain peripheral blood mononuclear cells. Use EasySep TM Human CD8+ T Cell Isolation Kit II sorting kit (Stemcell), magnet rack and sterile 5ml flow tube. After counting the cells, place them on ice, add 50ul / ml antibody, mix well and let stand at room temperature for 5 minutes, then add 50ul / ml magnetic beads, place the flow tube in the magnet rack and incubate at room temperature for 3 minutes, flip the magnet and flow tube, transfer the liquid in the flow tube to another clean sterile flow tube, and repeat twice. Cytokines CD3 (5ug / ml), CD28 (10ug / ml), PBS are configured to 100ul per well. Coat the U-shaped 96-well plate 24h in advance and incubate overnight at 4°C. When using it the next day, aspirate the PBS in the 96-well plate and place the separated CD8 +T cells were counted and plated at a density of 200,000 cells / well. After culturing in a 37°C constant temperature incubator for 24 hours, the cells were transferred to a new 96-well plate and IL-15 cytokine (25ng / ml) was added. After standing for 8 days, the cells were treated with 1.25μmol / L flutamide and 0.5μmol / L dihydrotestosterone (DHT) in the model control group for 72 hours, and then flow cytometry analysis was performed. The flow cytometry antibodies used were as follows: Anti-Human-CD62L-PE / Cyanine7 (BioLegend), Anti-Human-CD95(Fas)-BrilliantViolet 421 TM (BioLegend), Anti-Human-CD45RO-PE (BioLegend), Anti-Human-CD197(CCR7)-PE / Cyanine7 (BioLegend).

[0030] Results: By attaching Figure 3 We found that compared with the model group DHT, flutamide can improve CD8 + The proportion of T cells converted into effector T cells confirmed that flutamide can promote CD8 + T cell activation. The above results indicate that the new action pathway of flutamide is activation CD8 + T cells are transformed into effector T cells. Figure 3 (A) Isolation and culture of human peripheral blood mononuclear cells (PBMCs) Schematic diagram of CD8+ T cells and sorting diagram. Figure 3 (B) for sorting CD8 + T cells were stimulated with anti-CD3, anti-CD28 and IL-15 for 8 days, and then treated with flutamide or dihydrotestosterone (DHT) in the model control group. Flow cytometry was used to analyze the effector CD8 + T cells account for the total CD8 + The results showed that the flutamide group had a significantly higher CD8 T cell ratio than the model control group. + The proportion of T cells increased by 12%, which has a better CD8 + T activation effect.

[0031] The above-described embodiment is only a preferred solution of the present invention and does not limit the present invention in any form. There are other variations and modifications without exceeding the technical solution described in the claims.

Claims

1. The application of flutamide in the preparation of anticancer drugs for the treatment of head and neck squamous cell carcinoma.

2. A toxicity-reducing and synergistic composition for treating head and neck squamous cell carcinoma, characterized in that: It consists of flutamide and platinum chemotherapy drugs.

3. The toxicity-reducing and synergistic composition according to claim 2, characterized in that: The platinum chemotherapy drug is selected from one of cisplatin, carboplatin and oxaliplatin.

4. The toxicity-reducing and synergistic-enhancing composition according to claim 2, characterized in that: The mass ratio of flutamide: platinum chemotherapy drugs = 75:

2.

5. The toxicity-reducing and synergistic-enhancing composition according to claim 2, characterized in that: The dosage of flutamide is 25 mg / kg, once a day; the dosage of platinum chemotherapy drugs is 2 mg / kg, once every 3 days.

6. Use of the toxicity-reducing and synergistic-enhancing composition according to claim 2 in the preparation of anticancer drugs for treating head and neck squamous cell carcinoma.